Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

iCMLf Conversation: Genomics and Mutations in CML

  susan branford

Expert:

Professor Susan Branford
Head, Leukemia Unit, Genetis and Molecular Pathology, SA Pathology, Adelaide (Australia)


Program:
Genetics & Mutations in CML - Risk & Assessment

  • When to test for BCR::ABL1 kinase mutations?
  • NGS for BCR::ABL1 mutation analysis
  • Frequency of blood cancer-related mutations: Review of up to 500 patients
  • Studies of highly selected patients at diagnosis using NGS
  • Studies of patients in AP/BP using NGS
  • Case study: multiple competing clones drive progression and blast phase phenotype
  • Case study: clonal dynamics of two patients with mutated ASXL1 at diagnosis in chronic phase
  • Summary
  • Question & Answer Session:
    • What are your thoughts on the 35-base-pair insertion?
    • In the absence of single-cell sequencing, is it appropriate to draw the fishplot to represent the mutation clone size & substructure?
    • All these mutations which are subsequently arising in your patients that you have shown: Do you think that they were already present at diagnosis, and therefore a question of the sensitivity of the techniques you have used, or do you think they have been acquired while they were already in full remission?
    • When do you think it will be possible to incorporate genomic risk profile into therapy selection?

If you have any questions or comments to the speaker, please email info@cml-foundation.org.